CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Fluticasone furoate /vilanterol

Last Updated: October 29, 2013
Result type: Reports
Project Number: SR0358-000
Product Line: Reimbursement Review

Generic Name: Fluticasone furoate /vilanterol

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline

Therapeutic Area: Chronic Obstructive Pulmonary Disease (COPD)

Indications: Chronic Obstructive Pulmonary Disease (COPD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 18, 2014

Recommendation Type: List with criteria/condition